CSL (CSLLY) Stock Price, News & Analysis

Company Overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $86.05 to $86.80
• 50-Day Range: $77.06 to $88.99
• 52-Week Range: $70.22 to $109.00
• Volume: 33,304 shs
• Average Volume: 83,331 shs
• Market Capitalization: $83.76 billion
• P/E Ratio: N/A
• Dividend Yield: 1.39%
• Price Target: N/A
• Consensus Rating: Strong Buy

CSL Stock Analysis - MarketRank™

CSL scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for CSL.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.25%

Earnings Growth

Earnings for CSL are expected to grow by 14.25% in the coming year, from $3.58 to $4.09 per share.

Price to Earnings Growth Ratio

CSL has a PEG Ratio of 1.89. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

CSL has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of CSL have been sold short.

Short Interest Ratio / Days to Cover

CSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CSL has recently decreased by 47.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

CSL pays a meaningful dividend of 1.41%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

CSL does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, CSL will have a dividend payout ratio of 29.34% next year. This indicates that CSL will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of CSL have been sold short.

Short Interest Ratio / Days to Cover

CSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CSL has recently decreased by 47.68%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added CSL to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CSL insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.03% of the stock of CSL is held by institutions.

CSLLY Stock Analysis - Frequently Asked Questions

How have CSLLY shares performed this year?

CSL's stock was trading at $87.56 on January 1st, 2025. Since then, CSLLY shares have decreased by 1.2% and is now trading at $86.49.

How do I buy shares of CSL?

Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/12/2025
• Next Earnings (Estimated): 8/19/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CSLLY
• CIK: 1274152
• Web: www.csl.com.au
• Phone: (139) 389-1911
• Fax: 61-3-9389-1434
• Employees: 32,698
• Year Founded: 1904

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 24.16
• P/E Growth: 1.89
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 1.86
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $14.80 billion
• Price / Sales: 5.66
• Cash Flow: $4.03 per share
• Price / Cash Flow: 21.47
• Book Value: $20.07 per share
• Price / Book: 4.31

Miscellaneous

• Outstanding Shares: 968,420,000
• Free Float: N/A
• Market Cap: $83.76 billion
• Optionable: Not Optionable
• Beta: 0.82